
Browsing restrictions can be lifted for a fee.
-2.14%
Quest diagnostics incorporated
-3.61%
Avg of Sector
-2.16%
S&P500

Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2026Q1 | ||||
| 2026Q2 | ||||
| 2026Q3 | ||||
| 2026Q4 | ||||
| 2027Q1 |
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2025Q4 | |||||||
| 2025Q3 | |||||||
| 2025Q2 | |||||||
| 2025Q1 |
The most recent financial report for Quest diagnostics incorporated (DGX) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating DGX's short-term business performance and financial health. For the latest updates on DGX's earnings releases, visit this page regularly.
According to historical valuation range analysis, Quest diagnostics incorporated (DGX)'s current price-to-earnings (P/E) ratio is 23.38, placing it in the Overvalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning optimistic. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
According to the latest financial report, Quest diagnostics incorporated (DGX) reported an Operating Profit of 386M with an Operating Margin of 13.76% this period, representing a growth of 6.93% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, Quest diagnostics incorporated (DGX) announced revenue of 2.81B, with a Year-Over-Year growth rate of 7.06%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
As of the end of the reporting period, Quest diagnostics incorporated (DGX) had total debt of 6.38B, with a debt ratio of 0.39. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
At the end of the period, Quest diagnostics incorporated (DGX) held Total Cash and Cash Equivalents of 420M, accounting for 0.03 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, Quest diagnostics incorporated (DGX) achieved the “three margins increasing” benchmark, with a gross margin of 32.4%%, operating margin of 13.76%%, and net margin of 8.7%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess DGX's profit trajectory and future growth potential.
According to the past four quarterly reports, Quest diagnostics incorporated (DGX)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 2.21. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
Quest diagnostics incorporated (DGX)'s Free Cash Flow (FCF) for the period is 307M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 9.97% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
The latest valuation data shows Quest diagnostics incorporated (DGX) has a Price-To-Earnings (PE) ratio of 23.38 and a Price/Earnings-To-Growth (PEG) ratio of 14.28. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.